AK Medical Holdings Limited Stock

Equities

1789

KYG020141019

Medical Equipment, Supplies & Distribution

Delayed Hong Kong S.E. 11:09:50 2024-07-04 pm EDT 5-day change 1st Jan Change
4.34 HKD -1.36% Intraday chart for AK Medical Holdings Limited +0.70% -30.67%

Financials

Sales 2024 * 1.41B 194M 1.52B Sales 2025 * 1.78B 246M 1.92B Capitalization 4.6B 632M 4.94B
Net income 2024 * 264M 36.33M 284M Net income 2025 * 339M 46.65M 364M EV / Sales 2024 * 3.11 x
Net cash position 2024 * 203M 27.9M 218M Net cash position 2025 * 200M 27.46M 214M EV / Sales 2025 * 2.46 x
P/E ratio 2024 *
17.4 x
P/E ratio 2025 *
13.6 x
Employees 1,051
Yield 2024 *
1.55%
Yield 2025 *
2.03%
Free-Float 48.66%
More Fundamentals * Assessed data
Dynamic Chart
AK Medical Holdings Limited Declares Final Dividend for the Year Ended 31 December 2023 CI
AK Medical Holdings Limited Appoints Gao Wei as Independent Non-Executive Director CI
AK Medical Holdings' Surgical Robot Gets NMPA's Nod MT
Eric Wang to Retire as an Independent Non-Executive Director of AK Medical Holdings Limited CI
AK Medical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 18 July 2024 CI
AK Medical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
AK Medical Secures Regulatory Nod For Pelvic Implant MT
Ak Medical Holdings Limited Obtains the Certification from National Medical Products Administration CI
AK Medical Gets Certification for Acetabular Component of Hip Prosthesis MT
AK Medical Holdings Limited Obtains the Certification for Acetabular Component of Hip Prosthesis Class III Medical Devices Approved by the National Medical Products Administration CI
China Grants Certification for AK Medical Holdings' Surgical Robotic Arm MT
AK Medical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
AK Medical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2022, Payable on or Around 18 July 2023 CI
Chinese Regulator Approves AK Medical's Certification for Prosthetis System MT
AK Medical Holdings Limited Obtains the Certification for the Metal Additive Manufacturing Thoracolumbar Fusion Matching Prosthesis System Class III Medical Devices Approved by the National Medical Products Administration CI
More news
1 week-0.68%
Current month+2.09%
1 month-13.56%
3 months-14.06%
6 months-27.39%
Current year-29.71%
More quotes
1 week
4.27
Extreme 4.27
4.49
1 month
4.25
Extreme 4.25
5.29
Current year
3.89
Extreme 3.89
6.46
1 year
3.89
Extreme 3.89
8.00
3 years
3.50
Extreme 3.5
14.08
5 years
3.50
Extreme 3.5
27.65
10 years
1.75
Extreme 1.75
27.65
More quotes
Managers TitleAgeSince
Founder 54 15-07-16
Chief Executive Officer 56 15-07-16
Director of Finance/CFO 40 16-11-30
Members of the board TitleAgeSince
Director/Board Member 63 16-02-28
Director/Board Member 49 17-11-16
Chief Executive Officer 56 15-07-16
More insiders
Date Price Change Volume
24-07-04 4.34 -1.36% 436 000
24-07-04 4.4 0.00% 662,000
24-07-03 4.4 +0.69% 1,366,000
24-07-02 4.37 +1.39% 1,970,350
24-06-28 4.31 -0.92% 3,270,350

Delayed Quote Hong Kong S.E., July 04, 2024 at 04:09 am EDT

More quotes
AK MEDICAL HOLDINGS Ltd is an investment holding company principally engaged in design, develop, produce and market orthopedic implants and related products. The Company, along with its subsidiaries, operates its businesses through two segments, including China Orthopedic Implants segment and United Kingdom Orthopedic Implants segment. The Company's businesses mainly include hip and knee implants business, spine and trauma implants business, customized products and services, research and development business. The Company also engages in joints business, spine business, overseas business and digital orthopedics business. The Company mainly conducts its businesses in the domestic market and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.096 CNY
Average target price
7.441 CNY
Spread / Average Target
+81.64%
Consensus